Volume 27, Number 2—February 2021
Synopsis
Characteristics and Timing of Initial Virus Shedding in Severe Acute Respiratory Syndrome Coronavirus 2, Utah, USA
, Lindsey M. Duca, Perrine Marcenac, Elizabeth A. Dietrich, Christopher J. Gregory, Victoria L. Fields, Michelle M. Banks, Jared R. Rispens, Aron Hall, Jennifer L. Harcourt, Azaibi Tamin, Sarah Willardson, Tair Kiphibane, Kimberly Christensen, Angela C. Dunn, Jacqueline E. Tate, Scott Nabity, Almea M. Matanock, and Hannah L. Kirking
Table
Characteristics and symptoms of index case-patients and household contacts testing positive or negative for severe acute respiratory syndrome coronavirus 2 by real-time reverse transcription PCR in study of initial virus shedding in SARS-CoV-2, Utah, USA, April–May 2020*
| Characteristic | No. (%) |
||
|---|---|---|---|
| Index case-patients, n = 5 | SARS-CoV-2–positive contacts, n = 7 | SARS-CoV-2–negative contacts, n = 8 | |
| Age group, y | |||
| <18 | 1 (20.0) | 4 (57.1) | 2 (25.0) |
| 18–49 | 4 (80.0) | 3 (42.9) | 3 (37.5) |
| 50–64 | 0 | 0 | 1 (12.5) |
| >65 |
0 |
0 |
2 (25.0) |
| Sex | |||
| M | 4 (80.0) | 0 | 3 (37.5) |
| F |
1 (20.0) |
7 (100.0) |
5 (62.5) |
| Race or ethnicity | |||
| Non-Hispanic white | 5 (100.0) | 7 (100.0) | 7 (87.5) |
| Hispanic |
0 |
0 |
1 (12.5) |
| Underlying medical conditions | |||
| Any underlying condition | 2 (40.0) | 3 (42.9) | 6 (75.0) |
| Any chronic lung disease | 1 (20.0) | 0 | 2 (25.0) |
| Diabetes mellitus | 0 | 1 (14.3) | 0 |
| Any cardiovascular disease | 0 | 0 | 5 (62.5) |
| Any chronic renal disease | 0 | 0 | 1 (12.5) |
| Any immunocompromised condition | 1 (20.0) | 0 | 1 (12.5) |
| Other chronic condition | 1 (20.0) | 2 (28.6) | 1 (12.5) |
| No underlying medical condition |
3 (60.0) |
4 (57.1) |
2 (25.0) |
| Smoking or vaping status | |||
| Former history of smoking or vaping |
1 (20.0) |
0 |
1 (12.5) |
| Interactions with index case-patient | |||
| Intimate physical contact | N/A | 6 (85.7) | 2 (25.0) |
| Close contact only | N/A | 1 (14.3) | 4 (50.0) |
| No interaction reported |
N/A |
0 |
2 (25.0) |
| Symptoms | |||
| Any symptom |
5 (100.0) |
7 (100.0) |
7 (87.5) |
| CSTE categories | |||
| Classic† | 4 (80.0) | 5 (71.4) | 2 (25.0) |
| Nonclassic‡ | 4 (80.0) | 7 (100.0) | 5 (62.5) |
| Asyndromic§ |
5 (100.0) |
7 (100.0) |
7 (87.5) |
| Other categories | |||
| Neurologic¶ | 5 (100.0) | 7 (100.0) | 4 (50.0) |
| Lower respiratory# | 4 (80.0) | 6 (85.7) | 2 (25.0) |
| Upper respiratory** | 4 (80.0) | 6 (85.7) | 7 (87.5) |
| Constitutional†† | 4 (80.0) | 7 (100.0) | 5 (62.5) |
| Gastrointestinal‡‡ | 3 (60.0) | 2 (28.6) | 3 (37.5) |
*CSTE, Council of State and Territorial Epidemiologists; SARS-CoV-2, severe acute respiratory syndrome coronavirus disease 2. †Cough, shortness of breath, or discomfort breathing. ‡>2 of fever, myalgia, headache, chills, loss of taste or smell, or sore throat. §Any symptoms other than classic or nonclassic: fatigue, runny nose, nasal congestion, chest pain, wheezing, nausea or vomiting, or diarrhea. ¶Loss of taste (partial or complete), loss of smell (partial or complete), or headache. #Discomfort while breathing, wheezing, shortness of breath, chest pain, or cough (dry or productive). **Sore throat, nasal congestion, or runny nose. ††Chills, fever (measured or subjective), fatigue, or myalgia. ‡‡Abdominal pain, nausea or vomiting, or diarrhea.